Neonatal Hypoxic-Ischemic Brain Injury Model
Objective: To demonstrate that caspase inhibitors provide neuroprotection when administered with delayed timing after neonatal hypoxic-ischemic brain injury in rats
This is a Neonatal Hypoxic-Ischemic Brain Injury Model protocol using rat as the model organism. The procedure involves 5 procedural steps, 1 equipment items, 1 materials. Extracted from a 1998 paper published in Journal of Clinical Investigation.
Model and subjects
rat • Not specified • unknown • neonatal • Not specified
Study window
~3 hour study window | ~3 hours hands-on
Core workflow
Induce neonatal hypoxic-ischemic brain injury • Administer caspase inhibitor via intracerebroventricular injection • Administer caspase inhibitor via systemic injection
Primary readouts
- DNA laddering (marker of apoptosis)
- TUNEL-labeling (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling)
- Nuclei with condensed chromatin
- Caspase activation levels
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Induce neonatal hypoxic-ischemic brain injury
Establish the neonatal hypoxia-ischemia model in rat pups
Note: This is described as a well-characterized model
View evidence from paper
“In a well characterized model of neonatal hypoxia-ischemia, we demonstrate marked but delayed cell death”
Administer caspase inhibitor via intracerebroventricular injection
Inject boc-aspartyl(OMe)-fluoromethylketone directly into the cerebral ventricles at 3 hours post-injury
Note: Delayed administration timing is critical for neuroprotection
View evidence from paper
“Administration of boc-aspartyl(OMe)-fluoromethylketone, a pan-caspase inhibitor, was significantly neuroprotective when given by intracerebroventricular injection 3 h after cerebral hypoxia-ischemia”
Administer caspase inhibitor via systemic injection
Inject boc-aspartyl(OMe)-fluoromethylketone systemically in a delayed fashion after hypoxia-ischemia
Note: Systemic route also demonstrated significant neuroprotection
View evidence from paper
“systemic injections of boc-aspartyl(OMe)-fluoromethylketone also given in a delayed fashion, resulted in significant neuroprotection”
Assess cell death markers
Evaluate DNA laddering, TUNEL-labeling, and nuclei with condensed chromatin to characterize apoptotic cell death
Note: Multiple markers of apoptosis were examined
View evidence from paper
“there is prominent DNA laddering, TUNEL-labeling, and nuclei with condensed chromatin”
Measure caspase activation
Assess caspase activation following hypoxia-ischemia to determine temporal relationship with cell death
Note: Caspase activation timing was delayed relative to injury
View evidence from paper
“Caspase activation, which is required in many cases of apoptotic cell death, also followed a delayed time course after hypoxia-ischemia”